Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Shareholder Meeting (November 2024)
33 slides from Prescient Therapeutics's shareholder meeting presentation, Nov 14, 2024
Slide 1: 2024 AGM presentation
For personal use only 2024 AGM presentation ASX: PTX
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 3: Chair Address
For personal use only 3 Chair Address
Slide 4: Snapshot of 2024 Accomplishments
Snapshot of 2024 Accomplishments For personal use only • Encouraging data continues to unfold PTX-100 • Generating awareness amongst KOLs at key global conferences • Planning and preparation for Phase 2 in CTCL • Pre-clinical work largely concluded • Compelling body of data demonstrating ability to
Slide 5: PTX is entering a major inflection point
PTX is entering a major inflection point For personal use only Value PTX-100 Adapted from Future Healthcare Today , 2021 5
Slide 6: First in class targeted therapy
IST IN CLASS TARGETED THERAPY =) Yale University MOFFITT @®)
Slide 7: What we've been doing in 2024
What we’ve been doing in 2024 For personal use only • Phase 1b trial ongoing, 25 enrolled with one patient still on therapy. Following safety, responses to treatment and duration of responses. • PK analysis provides insights into dose levels and dosing schedules • Presenting data and networking at s
Slide 8: PTX-100 strategy focussing on speed to market
PTX-100 strategy focussing on speed to market For personal use only • Prescient will focus its upcoming Phase 2 trial on relapsed and refractory CTCL • Faster, smaller trial than broader TCL trial • Addresses more urgent medical need with less competition • Aiming for IND allowance by end year and o
Slide 9: Rationale of prioritising r/r CTCL for upcoming Ph2 trial
Rationale of prioritising r/r CTCL for upcoming Ph2 trial For personal use only CTCL PTCL • Higher confidence of PTX-100 in CTCL • PTCL is more prevalent than CTCL, but (more data; more responders) even though PTCL is still an unmet need, it has more existing and emerging competition • Greater need
Slide 10: What is Cutaneous T-cell Lymphomas (CTCL)?
What is Cutaneous T-cell Lymphomas (CTCL)? For personal use only • A rare type of cancer of white blood cells (T cells), normally involved in immune function. • These cancerous T cells travel to and live in the skin, where they grow and divide uncontrollably, attacking the skin. • CTCLs include grou
Slide 11: Relevant CTCL case study
Relevant CTCL case study For personal use only • Fusion protein of IL-2 and diphtheria toxin, developed by Lymphir Registration trial results: Citius and Dr Reddy’s • ORR: 36% • Purer version of Eisai’s Ontak (withdrawn from market in 2014 due to manufacturing issues) • Median duration of response:
Slide 12: PTX-100 Phase 1b study
For personal use only PTX-100 Phase 1b study 12
Slide 13: PTX-100: Ph1b Clinical Summary
PTX-100: Ph1b Clinical Summary For personal use only • Aims: Phase 1b to evaluate safety PK/PD • Design: Dose escalation in advanced malignancies; expansion cohort (n=25) in relapsed & refractory T cell lymphomas • Results: • Excellent safety Professor H. Miles Prince, AM • Target engagement at all
Slide 14: Drugs for relapsed/refractory TCL can be judged on criteria
Drugs for relapsed/refractory TCL can be judged on 3 criteria: For personal use only Expected SAFETY Serious Adverse Events >30% of the time RESPONSE ~30% patients respond RATES DURATION For those who respond: OF RESPONSE CTCL: 9-13 months PTCL: 3-4 months † Expected DoR 3-4 months for PTCL; 9-13 mo
Slide 15: PTX-100 stacks up favourably against all benchmark TCL criteria
PTX-100 stacks up favourably against all benchmark TCL criteria: For personal use only Expected PTX-100 SAFETY Serious Adverse Events >30% of the time RESPONSE RATES ~30% patients respond For those who respond: DURATION CTCL: 9-13 months OF RESPONSE PTCL: 3-4 months 15
Slide 16: PTX-100 Phase trial status
PTX-100 Phase 2 trial status For personal use only • In dialogue with US FDA. Areas of focus • Dose optimization ( a requirement for all companies as per Project Optimus) • Non-clinical data on drug-drug interactions • These are readily addressable • On track for IND submission imminently • IND allo
Slide 17: Potential PTX-100 development plan
Potential PTX-100 development plan For personal use only 2024 2025 2026 2027 2028 r/r CTCL Mono Ph2 registration Optimal dose r/r PTCL Mono Ph1b expansion Mono Ph 2 registration NB: Does not take into account the additional opportunities of combining PTX-100 with existing therapies 17
Slide 18: PTX-100 Summary
PTX-100 Summary For personal use only Progress Challenges Going forward • Phase 1b data continued to • Recruitment for rare diseases • IND submission and protocol impress finalisation (imminent) • CMC campaign ongoing – big • Presentation at global hem-onc jump from Ph1 to registration • IND and pro
Slide 19: Therapy platforms
i Prescient - ty = Therapeutics * ges \ tril THERAPY PLATFERMS
Slide 20: Challenges for the Cell Therapy sector
Challenges for the Cell Therapy sector For personal use only • Still largely in malaise; expensive to research and develop in a capital-constrained environment • Most CAR-T therapies that have been approved have still not resulted in profitability • Boxed warnings for CAR-T in early 2024 • Manufactu
Slide 21: Prescient positioned as 3rd party problem solver for cell therapy
A reminder that Prescient has deliberately positioned itself to be a 3rd party problem solver for cell therapy For personal use only challenges Safety & Control - Targeting - Safer Escape - More Production efficiency - effective Exhaustion Accessible & Trafficking affordable Tumor pe
Slide 22: PTX strategically positioned in an evolving field
PTX strategically positioned in an evolving field For personal use only Current generation CAR-Ts Emerging immune cell types Manufacturing methods Emerging targets Can enhance existing and Other cancers emerging cell therapies Beyond oncology Other cell therapy companies are potential customers, not
Slide 23: Cell Therapy Enhancements
For personal use only CELL THERAPY ENHANCEMENTS 23
Slide 24: CellPryme: enhancing cell therapies in two ways
CellPryme: enhancing cell therapies in two ways For personal use only MANUFACTURING ENHANCEMENT ADJUVANT THERAPY Non-disruptive additive Administered to patient during cell manufacturing concurrent with cell therapy 24
Slide 25: CellPryme Summary
CellPryme Summary For personal use only Progress Challenges Going forward • Pre-clinical studies largely concluded, • Third parties (particularly for • Publication of final data that includes new reinforcing very encouraging results CellPryme-A) having severe data on how CellPryme interacts with the
Slide 26: Universal, Next-Gen cell therapies
For personal use only Universal, Next-Gen cell therapies 26
Slide 27: Any immune cell to any target
Any immune cell → to any target For personal use only OmniCAR can use any type of targeting ligand… …with any immune cell Adapted from Powell, DJ et al, JACS; 2020 27
Slide 28: OmniCAR Summary
OmniCAR Summary For personal use only Progress Challenges Going forward • PTX team has been addressing • A hugely complex and multi-faceted, • Conclusion of problem-solving activities cytotoxicity of unarmed OmniCAR multi-disciplinary problem, with no to identify OmniCAR v2.0 cells. This is essentia
Slide 29: Summary
For personal use only Summary 29
Slide 30: Major catalysts to work towards next year
Major catalysts to work towards next year Prescient will continue to progress the development of programs across its pipeline. Some notable catalysts to For personal use only work towards include, but are not limited to: Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 IND Phase 2 PTX-100 submission IND tria
Slide 31: Aspirations for each program in years if they succeed
Aspirations for each program in 5 years if they succeed For personal use only Not everything will go to plan, but any one of these successes could be transformative for PTX • PTX-100 • Approved in r/r CTCL, with product sales • Registration study for r/r PTCL • In additional Phase 2 trials to domina
Slide 32: PTX is entering a major inflection point
PTX is entering a major inflection point For personal use only Value PTX-100 Adapted from Future Healthcare Today , 2021 32
Slide 33: For personal use only
For personal use only ASX: PTX
Prescient Therapeutics — Shareholder Meeting (November 2024) on 6ix